Jubilant Ingrevia has announced a contract development and manufacturing organisation (CDMO) contract for an estimated value of Rs 270 crore in the speciality chemicals business, spanning over three years with one of its international customers. The company will supply two key GMP intermediates for one of the ‘patented drugs’ of the innovator pharma customer. Both these products involve seven steps of specialised chemistry.  

The company was awarded these CDMO projects a few years back and with extensive work in R&D and Scale-up, it has successfully demonstrated its capability in process development, optimisation and scaling-up of complex chemistries. Commercial supplies of both these products will start from FY’23 onwards. The company will use the GMP facility to service this contract.

Rajesh Srivastava, CEO and MD, Jubilant Ingrevia shared, “The pursuit of growth is one of the key features of our strategy. Today’s announcement is in line with our strategy and commitment to growing our CDMO business of value-added GMP and Non-GMP intermediates. Our CDMO project pipeline for our pharmaceuticals and agrochemical continues to be strong and we stay committed to further strengthening our presence in the CDMO business, through a comprehensive and planned CAPEX.”